Basic Information
ID: ALA701680
Type: Functional
Description: Compound was evaluated for the inhibition of platelet aggregation, assessed turbidimetrically in citreated human platelet rich plasma (PRP)
Format: BAO_0000366
Organism: Homo sapiens
Tissue: Plasma
Target: Thromboxane A2 receptor(ALA2069)
Document: ALA1128161
Compound was evaluated for the inhibition of platelet aggregation, assessed turbidimetrically in citreated human platelet rich plasma (PRP): 1
Activity Charts
Bioactivity
Activity Types for Assay ALA701680
IC50
Compound Summary
| Parent Molecular Weight | ALogP | Polar Surface Area |
|---|---|---|
| 403.49 | 3.89 | 3.89 |
| 383.49 | 3.59 | 3.59 |
| 391.44 | 2.49 | 2.49 |
| 422.33 | 3.63 | 3.63 |
| 387.45 | 3.28 | 3.28 |
| 398.44 | 2.23 | 2.23 |
| 369.46 | 3.28 | 3.28 |
| 387.45 | 3.28 | 3.28 |
| 389.42 | 2.60 | 2.60 |
| 387.47 | 2.66 | 2.66 |
| 419.52 | 4.44 | 4.44 |
| 424.32 | 4.20 | 4.20 |
| 418.44 | 2.26 | 2.26 |
| 438.35 | 4.59 | 4.59 |
| 349.45 | 3.17 | 3.17 |
| 409.43 | 2.63 | 2.63 |
| 403.90 | 3.94 | 3.94 |
| 335.43 | 2.86 | 2.86 |
| 389.46 | 3.50 | 3.50 |
| 400.50 | 3.80 | 3.80 |
| 399.51 | 4.41 | 4.41 |
| 405.46 | 2.74 | 2.74 |
| 394.45 | 3.16 | 3.16 |
| 367.44 | 3.39 | 3.39 |
| 363.48 | 3.56 | 3.56 |
| 389.88 | 3.55 | 3.55 |
| 400.43 | 2.80 | 2.80 |
| 391.41 | 3.17 | 3.17 |
| 373.42 | 3.03 | 3.03 |
| 369.46 | 3.20 | 3.20 |
| 349.45 | 3.25 | 3.25 |
| 414.46 | 3.19 | 3.19 |
| 404.32 | 4.17 | 4.17 |
| 369.87 | 3.52 | 3.52 |
| 380.42 | 2.77 | 2.77 |
| 369.46 | 3.62 | 3.62 |
| 367.44 | 3.25 | 3.25 |
| 385.46 | 2.71 | 2.71 |
| 371.41 | 3.14 | 3.14 |
| 381.47 | 3.64 | 3.64 |
| 389.46 | 3.65 | 3.65 |
| 403.90 | 3.79 | 3.79 |
| 355.43 | 2.89 | 2.89 |
| 383.49 | 3.45 | 3.45 |
| 353.42 | 3.00 | 3.00 |
| 373.45 | 2.35 | 2.35 |
| 371.43 | 2.46 | 2.46 |
| 367.47 | 2.63 | 2.63 |
| 387.45 | 3.42 | 3.42 |
| 405.44 | 3.56 | 3.56 |
| 353.44 | 2.33 | 2.33 |
| 401.48 | 3.67 | 3.67 |
| 420.51 | 3.83 | 3.83 |